圣诺生物(688117.SH)：维培那肽原料药获得上市申请批准

Core Viewpoint - The company, Shengnuo Biopharmaceutical (688117.SH), has received approval from the National Medical Products Administration for the marketing application of its active pharmaceutical ingredient, Vepagliflozin [1] Group 1: Company Developments - Shengnuo Biopharmaceutical's wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., has recently obtained the approval notice for Vepagliflozin from the National Medical Products Administration [1] - Vepagliflozin is a polyethylene glycol (PEG) modified version of Exenatide, which acts as a GLP-1 receptor agonist, mimicking the physiological effects of natural human GLP-1 [1] Group 2: Product Information - The drug enhances insulin secretion in a glucose-dependent manner, thereby lowering blood sugar levels, and is intended for the treatment of type 2 diabetes and obesity [1]